Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables - Net: 2022-2025

Historic Receivables - Net for Corvus Pharmaceuticals (CRVS) over the last 2 years, with Sep 2025 value amounting to $32,000.

  • Corvus Pharmaceuticals' Receivables - Net fell 54.29% to $32,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $32,000, marking a year-over-year decrease of 54.29%. This contributed to the annual value of $75,000 for FY2024, which is 188.46% up from last year.
  • Corvus Pharmaceuticals' Receivables - Net amounted to $32,000 in Q3 2025, which was down 62.79% from $86,000 recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Receivables - Net peaked at $588,000 during Q4 2022, and registered a low of $11,000 during Q3 2023.
  • For the 3-year period, Corvus Pharmaceuticals' Receivables - Net averaged around $48,889, with its median value being $35,000 (2024).
  • Per our database at Business Quant, Corvus Pharmaceuticals' Receivables - Net slumped by 95.58% in 2023 and then spiked by 536.36% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Receivables - Net (Quarterly) stood at $588,000 in 2022, then plummeted by 95.58% to $26,000 in 2023, then skyrocketed by 188.46% to $75,000 in 2024, then slumped by 54.29% to $32,000 in 2025.
  • Its last three reported values are $32,000 in Q3 2025, $86,000 for Q2 2025, and $79,000 during Q1 2025.